ArticleCancer gene therapy2021

Correction: A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy.

Johanna Pruller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.